NCT06313086View on ClinicalTrials.gov

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

442

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 29, 2028

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

DP303c

intravenous injection

DRUG

trastuzumab emtansine

intravenous injection

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY